204 related articles for article (PubMed ID: 21129837)
1. Delayed hypersensitivity challenged by subcutaneous Bemiparin.
Moreno Escobosa MC; Moya Quesada MC; Granados SC; Amat López J
Allergol Immunopathol (Madr); 2011; 39(5):309-10. PubMed ID: 21129837
[No Abstract] [Full Text] [Related]
2. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
[TBL] [Abstract][Full Text] [Related]
3. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux.
Maetzke J; Hinrichs R; Schneider LA; Scharffetter-Kochanek K
Allergy; 2005 Mar; 60(3):413-5. PubMed ID: 15679737
[No Abstract] [Full Text] [Related]
4. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study.
Gaigl Z; Pfeuffer P; Raith P; Bröcker EB; Trautmann A
Br J Haematol; 2005 Feb; 128(3):389-92. PubMed ID: 15667543
[TBL] [Abstract][Full Text] [Related]
5. Delayed-type hypersensitivity to heparins: different patterns of cross-reactivity.
Palacios Colom L; Alcántara Villar M; Luis Anguita Carazo J; Ruiz Villaverde R; Quiralte Enríquez J
Contact Dermatitis; 2008 Dec; 59(6):375-7. PubMed ID: 19076893
[No Abstract] [Full Text] [Related]
6. Delayed-type hypersensitivity to heparin with tolerance of its intravenous administration.
Irion R; Gall H; Peter RU
Contact Dermatitis; 2000 Oct; 43(4):249-50. PubMed ID: 11011948
[No Abstract] [Full Text] [Related]
7. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
8. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
Koch P
Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
[TBL] [Abstract][Full Text] [Related]
9. Abdominal wall hematomas associated with low-molecular-weight heparins: an important complication in older adults.
Nourbakhsh E; Anvari R; Nugent K
J Am Geriatr Soc; 2011 Aug; 59(8):1543-5. PubMed ID: 21848819
[No Abstract] [Full Text] [Related]
10. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
[TBL] [Abstract][Full Text] [Related]
11. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
12. Delayed hypersensitivity to enoxaparin.
Cabañas R; Caballero MT; López-Serrano MC; Díaz R; Contreras J; Barranco P; Moreno-Ancillo A
J Investig Allergol Clin Immunol; 1998; 8(6):383-4. PubMed ID: 10028487
[TBL] [Abstract][Full Text] [Related]
13. Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
Colagiovanni A; Rizzi A; Buonomo A; De Pasquale T; Pecora V; Sabato V; Aruanno A; Pascolini L; Nucera E; Schiavino D
Contact Dermatitis; 2010 Aug; 63(2):107-8. PubMed ID: 20629676
[No Abstract] [Full Text] [Related]
14. Tolerance of desirudin in a patient with generalized eczema after intravenous challenge with heparin and a delayed-type skin reaction to high and low molecular weight heparins and heparinoids.
Schiffner R; Glässl A; Landthaler M; Stolz W
Contact Dermatitis; 2000 Jan; 42(1):49. PubMed ID: 10644031
[No Abstract] [Full Text] [Related]
15. Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels.
Rocha E; Gómez-Outes A; Martínez González J; Kakkar VV
Thromb Haemost; 2005 Nov; 94(5):1109-10. PubMed ID: 16363259
[No Abstract] [Full Text] [Related]
16. Eczema-like plaques secondary to enoxaparin.
White JM; Munn SE; Seet JE; Adams N; Clement M
Contact Dermatitis; 2006 Jan; 54(1):18-20. PubMed ID: 16426288
[TBL] [Abstract][Full Text] [Related]
17. Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic sodium-heparin.
Koch P; Hindi S; Landwehr D
Contact Dermatitis; 1996 Feb; 34(2):156-8. PubMed ID: 8681559
[No Abstract] [Full Text] [Related]
18. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
19. [Efficient ambulatory and post-discharge thromboprophylaxis with fully automated pens].
Höntzsch D; Scheffer J; Hafner S
Langenbecks Arch Chir Suppl Kongressbd; 1997; 114():1060-2. PubMed ID: 9574332
[TBL] [Abstract][Full Text] [Related]
20. The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514-17.
Ludwig RJ; Schindewolf M; Lindhoff-Last E; Boehncke WH
Br J Dermatol; 2008 Apr; 158(4):849-51. PubMed ID: 18205866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
